Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 460

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 9A
Chunk 460
---

        Total
         
        $
        26,887

F-26

12. ACCRUED EXPENSESThe following table summarizes the Company’s accrued expenses for each of the periods indicated: 

        As of December 31,

        2024

        2023

        (in thousands)

        Product revenue related reserves
         
        $
        109,157

        $
        100,075

        Accrued employee compensation costs

        91,119

        78,732

        Accrued contract manufacturing costs

        77,842

        33,024

        Accrued clinical and pre-clinical costs

        26,849

        34,669

        Accrued professional fees

        17,691

        17,187

        Accrued income taxes

        17,391

        13,766

        Accrued royalties

        16,625

        12,070

        Accrued fixed assets

        5,305

        3,231

        Accrued interest expense

        4,192

        4,395

        Accrued milestone and license expense

        2,000

        11,375

        Other

        5,342

        6,473

        Total accrued expenses
         
        $
        373,513

        $
        314,997

13. INDEBTEDNESS 2027 Convertible Notes and Related Transactions     Issuance and Capped Call TransactionsIn September 2022, the Company issued $1,150.0 million aggregate principal amount of convertible senior notes due on September 15, 2027. The 2027 Notes are senior unsecured obligations of the Company and bear interest at a rate of 1.25% per annum, payable semi-annually in cash on each March 15 and September 15, commencing on March 15, 2023. The net proceeds were $1,126.7 million after deducting the discounts and offering expenses of $23.3 million, which is amortized under the effective interest method and recorded as additional interest expense over the life of the 2027 Notes. The effective interest rate on the 2027 Notes is 1.67%. The aggregate issuance of the 2027 Notes includes the issuance of $20.0 million in aggregate principal amount of